In January 2019, Luye Pharma granted AstraZeneca exclusive rights to promote Xuezhikang Capsules in mainland China 

• AstraZeneca is responsible for the exclusive promotion of Xuezhikang capsules in mainland China, while Luye Pharma retains asset rights, commercial sales rights, the registration permit, all intellectual property rights and other product-related rights aside from product promotion.
• This is the first time that a multinational pharmaceutical company has gained exclusive authorization in China to promote an innovative drug developed by a Chinese pharmaceutical company.

In March 2019, Luye Pharma and AstraZeneca signed a Memorandum of Understanding for intent to form a new strategic partnership jointly exploring opportunities for Xuezhikang Capsules in global markets other than China

• Luye Pharma and AstraZeneca intend to deepen their strategic partnership outside of China by leveraging mutual resources to jointly explore global opportunities for Xuezhikang Capsules. 
• Both parties will jointly contribute to the "The Belt and Road" initiative and "Healthy China" development initiatives. 
• By tapping into AstraZeneca’s resources in China and abroad, and Luye Pharma’s product advantages respectively, Xuezhikang Capsules are expected to reach more countries and regions globally, further boosting the internationalization effort for innovative domestic drug.

In August 2019, Luye Pharma granted AstraZeneca exclusive rights to promote Xuezhikang Capsules in Singapore

• Luye Pharma granted AstraZeneca exclusive rights to promote Lipascor^® in Singapore. Lipascor^® is the registered brand name of Xuezhikang Capsules in that country.